ArticleFrontiers in oncology2025
Establishment and validation of a prognostic model based on vasculogenic mimicry-related gene clustering in ovarian cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As a critical prognostic factor in ovarian cancer which is the most lethal gynecologic malignancy, vasculogenic mimicry (VM) has not been systematically incorporated into prognostic evaluation frameworks in ovarian cancer (OC). This underscores the necessity to develop and validate a gene subtyping-based prognostic model through comprehensive analysis of VM-related biomarkers. Methods: This study integrated multi-omics data from TCGA, GEO and GTEx, forming a primary set and an external validation cohort. Through literature mining, 28 VM-related genes were identified. Univariate Cox and LASSO regression distilled 9 genes as vasculogenic mimicry-related prognostic index (VMRPI), establishing a risk model validated by ROC and constructing a nomogram with clinical prognostic factors. Consensus clustering stratified patients into VM-high/-low subgroups. Multi-angle assessments connected risk scores with tumor mutational burden, immune infiltration, and chemotherapy sensitivity. Clinical validation encompassed IHC-PAS detection of VM structures in 36 HGSOC paraffin specimens and qRT-PCR confirmation of gene expression in matched frozen tissues. Results: vasculogenic mimicry-related genes (VMGs) exhibited differential expressions in HGSOC versus normal tissues, with consensus clustering stratifying 474 patients into prognostically distinct VM-high/low subgroups. Prognosis-associated DEGs (n=758) enriched in ECM-receptor and PI3K-AKT pathways. A 9-gene prognostic model demonstrated robust predictive accuracy. Risk scores correlated with immune infiltration and drug sensitivity. Multivariate-validated nomogram integrating clinical factors and risk scores achieved precise survival prediction. IHC-PAS confirmed VM structures, with VM-positive cases showing upregulated VMGs and VMRPIs. Conclusions: VMG-based stratification revealed distinct prognostic ovarian cancer subgroups and a 9-VMRPI demonstrated robust prognostic power with validated immune-microenvironment, drug-response associations, IHC-PAS staining, and qRT-PCR confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.